Topics

Medulloblastoma | Treatment | Immunotherapy | CAR-T-cells

Home > Publications > Topics > Medulloblastoma > Treatment > Immunotherapy > CAR-T-cells

Ni H, Reitman ZJ, Zou W, Akhtar MN, Paul R, Huang M, Zhang D, Zheng H, Zhang R, Ma R, Ngo G, Zhang L, Diffenderfer ES, Motlagh SAO, Kim MM, Minn AJ, Dorsey JF, Foster JB, Metz J, Koumenis C, Kirsch DG, Gong Y, Fan Y.
FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy.
Nat Cancer. 2025 Feb 5. doi: 10.1038/s43018-025-00905-6. PMID: 39910249. Laboratory investigation˰ ˍ

Lira MC, Vanpouille-Box C, De Martino M.
Harnessing FLASH irradiation to improve immunotherapy of medulloblastoma.
Trends Cancer. 2025 Mar 6:S2405-8033(25)00053-6. doi: 10.1016/j.trecan.2025.02.005. PMID: 40055118. Comment˰ ˍ
RELATED ARTICLE
Ni H, Reitman ZJ, Zou W, Akhtar MN, Paul R, Huang M, Zhang D, Zheng H, Zhang R, Ma R, Ngo G, Zhang L, Diffenderfer ES, Motlagh SAO, Kim MM, Minn AJ, Dorsey JF, Foster JB, Metz J, Koumenis C, Kirsch DG, Gong Y, Fan Y.
FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy.
Nat Cancer. 2025 Feb 5. doi: 10.1038/s43018-025-00905-6. PMID: 39910249. Laboratory investigation˰ ˍ

Eksteen C, Riedemann J, Johnson H, Engelbrecht AM.
Literature review: CAR T-cell therapy as a promising immunotherapeutic approach for medulloblastoma.
Rev Neurol (Paris). 2025 Aug 5:S0035-3787(25)00555-7. doi: 10.1016/j.neurol.2025.07.005. PMID: 40764212. Review. ˍ

Ronsley R, Huang W, Rohlf E, Seidel K, Brown C, Beebe A, Rawlings-Rhea SD, Lindgren C, Sad T, Crotty EE, Leary SES, Thomsen A, Beckstrom AR, Holtzclaw SL, Hoeppner C, Hurst D, MacQuivey M, Goldstein HE, Browd SR, Hauptman JS, Lee A, Ojemann JG, Wright JN, Albert CM, Pinto N, Gustafson JA, Ho O, Pattabhi S, Summers C, Annesley C, Wendler JN, Gust J, Gardner RA, Park JR, Jensen MC, Vitanza NA.
Intracerebroventricular B7-H3-targeting CAR T cells for non-pontine DMG and recurrent/refractory pediatric CNS tumors: a phase 1 trial.
Neuro Oncol. 2026 Jul 25:noag171. doi: 10.1093/neuonc/noag171. PMID: 42503899. Trial registration ID: NCT04185038˰ ˍ